Biologics
Pharmaceuticals
Revelyx Bio Phase 2 data back recombinant liquid botulinum toxin YY003
YY003 hit its composite primary endpoint in 80.8% of participants at the 40-unit dose, with rapid onset by week one and no neutralising
YY003 hit its composite primary endpoint in 80.8% of participants at the 40-unit dose, with rapid onset by week one and no neutralising